D.E. Shaw & Co
PACB icon

D.E. Shaw & Co’s Pacific Biosciences PACB Stock Holding History

D.E. Shaw & Co’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-52,000
Closed -$1.82M – 5151
2021
Q2 		$1.82M Buy
+52,000
New +$1.51M ﹤0.01% 3035

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

D.E. Shaw & Co's PACB Position: Q1 2026 in Review

D.E. Shaw & Co reduced its Pacific Biosciences (PACB) stake by 18% in Q1 2026, selling an estimated $1.43M and leaving 3,637,547 shares worth $4.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2211.

D.E. Shaw & Co first reported a position in PACB in Q2 2013 and has held it in 45 quarters since. The position peaked at $39.5M in Q3 2021. 229 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

  • D.E. Shaw & Co held 3,637,547 shares of Pacific Biosciences worth $4.8M as of Q1 2026.
  • D.E. Shaw & Co sold 800,726 Pacific Biosciences shares in Q1 2026, an estimated $1.43M.
  • Pacific Biosciences made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #2211 holding.
  • D.E. Shaw & Co first reported a position in Pacific Biosciences in Q2 2013 and has held it in 45 quarters since.
  • D.E. Shaw & Co's Pacific Biosciences position peaked at $39.5M in Q3 2021.
  • 229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.